Skip to content

Educational content only. Not investment advice: no price targets or buy and sell recommendations of our own.

Companies / CRISPR Therapeutics

CRSP

CRISPR Therapeutics

11 active clinical studies registered on ClinicalTrials.gov, the most advanced in Phase 3. Next estimated primary completion: 6 Jun 2027.

Clinical pipeline

Primary completionPhaseStatusCondition and study
6 Jun 2027 Phase 3? Active, not recruiting Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) · NCT05329649
Jun 2027 Phase 1? Recruiting Cardiovascular, Metabolic Disease, Dyslipidemias
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias · NCT07491172
14 Nov 2027 Phase 3? Active, not recruiting Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) · NCT05356195
1 Jul 2028 Phase 1/2? Recruiting Hypertension
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension · NCT07758634
30 Dec 2029 Phase 1/2? Not yet recruiting Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease · NCT07804004
Jan 2030 Phase 1/2? Recruiting B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies · NCT05643742
30 Jun 2030 Phase 1/2? Not yet recruiting Alpha-1 Antitrypsin Deficiency (AATD)
A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD) · NCT07850076
31 Dec 2031 Phase 1? Recruiting SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease · NCT06925542
Dec 2033 Phase 1/2? Recruiting Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease · NCT07549698
Aug 2038 N/A Enrolling by invitation Hematologic Malignancy, Solid Malignancy
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies · NCT06208878
30 Sep 2039 Phase 3? Enrolling by invitation Beta-Thalassemia, Thalassemia, Sickle Cell Disease
A Long-term Follow-up Study in Participants Who Received CTX001 · NCT04208529

Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.

Recent news

Headlines from other publications, linked to the original. We do not rewrite or summarise them. Analyst ratings and price targets are the opinion of the cited source, not ours.